文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Matsunaga T, Ohyama S, Takehara S, Kabashima K, Moriyama S, Tsuzuki J, Ikeda H, Suematsu M, Akizuki K, Fujimoto K

Kumamoto Prefectural Tomiai Hospital, Japan.

Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(4):533-9. doi: 10.1016/0278-5846(88)90112-1.

In a double-blind placebo-controlled study of 37 patients with tardive dyskinesia, the therapeutic effect of ceruletide was evaluated. 2. The patients were assigned at random to two groups that received either intramuscular injections of 0.8 micrograms/kg of ceruletide or placebo once weekly for 4 weeks. Conventional neuroleptic medication was not changed 3 weeks prior to and throughout the study period. Tardive dyskinesia was assessed using the Abnormal Involuntary Movement Scale over an 8-week period. 3. Ceruletide had a more pronounced effect on TD than the placebo however, because of the limited number of subjects examined, the difference between the two groups was not significant. Ceruletide was more effective than placebo in patients under 60 years of age (p less than 0.05) and whose antipsychotic medication was mainly butyrophenones. 4. No serious side effect was noted. 5. The findings suggested that ceruletide therapeutically benefits patients with tardive dyskinesia.

在一项针对37例迟发性运动障碍患者的双盲安慰剂对照研究中，评估了 Ceruletide 的治疗效果。2. 患者被随机分为两组，一组每周接受一次0.8微克/千克 Ceruletide 的肌肉注射，另一组接受安慰剂注射，共持续4周。在研究前3周及整个研究期间，常规抗精神病药物治疗不变。在8周的时间里，使用异常不自主运动量表对迟发性运动障碍进行评估。3. Ceruletide 对迟发性运动障碍的影响比安慰剂更为显著，然而，由于所检查的受试者数量有限，两组之间的差异并不显著。Celuletide 在60岁以下且抗精神病药物主要为丁酰苯类的患者中比安慰剂更有效（p小于0.05）。4. 未观察到严重的副作用。5. 研究结果表明，Celuletide 对迟发性运动障碍患者具有治疗益处。

Matsunaga T, Ohyama S, Takehara S, Kabashima K, Moriyama S, Tsuzuki J, Ikeda H, Suematsu M, Akizuki K, Fujimoto K

Kumamoto Prefectural Tomiai Hospital, Japan.

Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(4):533-9. doi: 10.1016/0278-5846(88)90112-1.

In a double-blind placebo-controlled study of 37 patients with tardive dyskinesia, the therapeutic effect of ceruletide was evaluated. 2. The patients were assigned at random to two groups that received either intramuscular injections of 0.8 micrograms/kg of ceruletide or placebo once weekly for 4 weeks. Conventional neuroleptic medication was not changed 3 weeks prior to and throughout the study period. Tardive dyskinesia was assessed using the Abnormal Involuntary Movement Scale over an 8-week period. 3. Ceruletide had a more pronounced effect on TD than the placebo however, because of the limited number of subjects examined, the difference between the two groups was not significant. Ceruletide was more effective than placebo in patients under 60 years of age (p less than 0.05) and whose antipsychotic medication was mainly butyrophenones. 4. No serious side effect was noted. 5. The findings suggested that ceruletide therapeutically benefits patients with tardive dyskinesia.

在一项针对37例迟发性运动障碍患者的双盲安慰剂对照研究中，评估了 Ceruletide 的治疗效果。2. 患者被随机分为两组，一组每周接受一次0.8微克/千克 Ceruletide 的肌肉注射，另一组接受安慰剂注射，共持续4周。在研究前3周及整个研究期间，常规抗精神病药物治疗不变。在8周的时间里，使用异常不自主运动量表对迟发性运动障碍进行评估。3. Ceruletide 对迟发性运动障碍的影响比安慰剂更为显著，然而，由于所检查的受试者数量有限，两组之间的差异并不显著。Celuletide 在60岁以下且抗精神病药物主要为丁酰苯类的患者中比安慰剂更有效（p小于0.05）。4. 未观察到严重的副作用。5. 研究结果表明，Celuletide 对迟发性运动障碍患者具有治疗益处。